Thursday, October 05, 2017 8:48:56 AM
However, lets discuss my first point. Just how complicated could this first deal be? Lets pretend that BP is in love with Brilacidin for UP/UC and the future Crohns. Lets pretend that single BP - lets call them Pfizer is also now interested in the OM side of Brilacidin as well. Pfizer has the CDA signed so they can look under the hood in more detail without mention and they are loving what they see. They have had their team investigate and do their DD on the drugs and again love it, however they are now more curious about the Anti-Fungal properties but do not want the Absssi anti-biotic portion, so they want to look further. Possibly BP 2 - lets call them Celgene is extremely interested in OM alone and will commit to a partnership based on the results of the phase 2 that will be released in 1 month. BP3 - lets call them J&J loves the topical application and continue to test the properties.
I am just thinking that so far the science has been SPOT ON - 100% successful and unbelievably promising. We know that Leo brought on Art to work with BP. We know that we have "MULTIPLE" CDA's signed. We know that the communication from Leo to shareholders has been harnessed. The PR's that we get are very limited and very straight forward for the past year or so.
I would love to sit down with Art, Leo and Dr. M and ask what their overall goal is, because at this point there are so many ways this can go from a partnership view, that I think we just have to sit tight wait for the phase 2 data coming in the next 3 months and see what happens after.
IMO - If Prurisol really outperforms Otezla, I would think that will be our first deal because it is pretty straightforward. As Georgiii says there could be many other applications for P, but for now we are just testing Psoriasis and that market is substantial especially looking for ORAL drugs.
just my morning coffee thoughts...
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM